Considerations for the Use of DREADDs in Behavioral Neuroscience

Neuropsychopharmacology Podcast

Content provided by Alex Thurrell and Nature Publishing Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alex Thurrell and Nature Publishing Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

6y ago 9:18

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on October 14, 2022 03:13 (1+ y ago). Last successful fetch was on September 06, 2022 23:30 (1+ y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

There's a technology that's proven to be increasingly useful in the past decade -- it's called DREADD, or "designer receptors exclusively activated by designer drugs." The current approach is to create a designer receptor that is unlocked by the drug, clozapine-n-oxide, or CNO. Researchers have used it to study the function of populations of neurons or of particular pathways in the brains in rodents, by using the DREADD technique to turn on and off these neurons or pathways. However, last year, a paper published in the journal Science called the use of DREADDs into question. Some people interpreted the paper as an overall indictment of the DREADD technology, though this wasn't the original intent of the authors. Listen to Neuropsychopharmacology's latest podcast to learn more!

Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

45 episodes

#Alex Thurrell #Nature Publishing Group #Neuroscience #Science #Natural Sciences #Pharmacology #Medicine